← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	1,750	+76	+5%	$128B
2	2 Danaher DHR $158B	1,584	+82	+5%	$99.5B
3	3 Novartis NVS $279B	1,129	-3	-0.3%	$20.8B
4	4 Regeneron Pharmaceuticals REGN $80.1B	933	+117	+14%	$57.9B
5	5 Illumina ILMN $41B	892	+68	+8%	$50.2B
6	6 Agilent Technologies A $49.1B	747	+31	+4%	$24B
7	7 Charles River Laboratories CRL $14.4B	466	+52	+13%	$8.14B
8	8 Revvity RVTY $17B	464	+41	+10%	$10.2B
9	9 Sarepta Therapeutics SRPT $1.78B	409	+43	+12%	$11.9B
10	10 DELISTED CATALENT, INC. CTLT	381	+55	+17%	$11.9B
11	11 Ionis Pharmaceuticals IONS $7.1B	376	+13	+4%	$7.09B
12	12 Alnylam Pharmaceuticals ALNY $30B	375	+44	+13%	$16.5B
13	13 Guardant Health GH $21.9B	325	+37	+13%	$6.85B
14	14 DELISTED bluebird bio BLUE	278	+31	+13%	$3.94B
15	15 CRISPR Therapeutics CRSP $4.86B	276	+19	+7%	$2.91B
16	16 Qiagen QGEN $9.41B	276	+16	+6%	$6.21B
17	17 Azenta AZTA $1.63B	269	+18	+7%	$3.24B
18	18 Arrowhead Research ARWR $8.25B	250	+9	+4%	$2.98B
19	19 Editas Medicine EDIT $349M	238	+39	+20%	$1.61B
20	20 Bruker BRKR $8.47B	227	-13	-5%	$4.27B
21	NVTA 21 DELISTED Invitae Corporation NVTA	224	+44	+24%	$3.98B
22	22 DELISTED SANGAMO THERAPEUTICS INC SGMO	205	+15	+8%	$691M
23	23 PTC Therapeutics PTCT $4.98B	203	0	0%	$3.47B
24	24 Fate Therapeutics FATE $232M	202	+46	+29%	$2.95B
25	25 Adaptive Biotechnologies ADPT $4.09B	196	+49	+33%	$4.89B